Weight loss medications like Wegovy and Zepbound are gaining popularity as millions turn to them for quick results and potential health benefits.

But recent weak U.S. prescription data is leading some investors and analysts to question whether that stellar run, which ...

Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Eli Lilly ( LLY 1.21%) and Novo Nordisk ( NVO 2.66%) were early leaders in the development of GLP-1 agonists, and dominate the market. Research from MarketsandMarkets suggests that annual global sales ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

The next generation of groundbreaking weight loss drugs used by millions is just over the horizon - and they won't require ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, ...

A new oral weight loss pill shows results similar to Ozempic and Wegovy injections in the treatment of obesity.